Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Enhancing GIST Patient Care: The Importance of Collaborating with Sarcoma Centres
June 2025
This series of short videos features expert opinions regarding the management of gastrointestinal stromal tumors (GIST). Each expert…
Read more
12 Dec 2015
Myeloma education today
Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual…
12 Dec 2015
Out-of-hours support for cancer patients with a modified UKONS telephone triage tool
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal…
12 Dec 2015
Tenovus Cancer Care ‘Sing with Us’ choirs
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care…
12 Dec 2015
UKONS: Bringing the nursing community together
Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology…
12 Dec 2015
Healthy lifestyle choices for patients with cancer
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS…
12 Dec 2015
Drug development for metastatic castration-resistant prostate cancer
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…
12 Dec 2015
Opportunities and challenges in immuno-oncology
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK…
12 Dec 2015
Defining patient safety at UKONS Annual Conference 2015
Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery…
12 Dec 2015
Motivational interviewing in healthcare
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching…
12 Dec 2015
Prevention and treatment of chemotherapy-induced nausea and vomiting
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust…
12 Dec 2015
ManVan: Mobile cancer support for prostate, testicular and penile cancer
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care…
12 Dec 2015
Evaluating the experience of surviving at least five years after a prostate cancer diagnosis
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS…
11 Dec 2015
Improving adherence to oral therapies in clinical practice
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton…
11 Dec 2015
Telephone assessment service for patients receiving ipilimumab for metastatic melanoma
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The Clatterbridge…
11 Dec 2015
Integrating psychological support and physical activity interventions in cancer care
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire…
11 Dec 2015
Improving survivorship services in haemato-oncology
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western Hospital…
11 Dec 2015
Optimising the assessment of sexuality in oncology
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University…
11 Dec 2015
A new model of care for lung cancer patients
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of…
11 Dec 2015
Developing a self-management programme to support prostate and testicular cancer survivors
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management needs…
11 Dec 2015
Defining the elements of the acute oncology nursing role
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal…
11 Dec 2015
Chemotherapy-induced nausea and vomiting – a nurse’s perspective
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of Warwick…
11 Dec 2015
Physical activity, obesity and cancer
Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There is now an increasingly large…
11 Dec 2015
The use of supplements to complement a healthy and balanced diet for prostate cancer patients
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects of Pomi-T on prostate-specific…
11 Dec 2015
Strategies to cope with cancer therapy side-effects
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert…
11 Dec 2015
The importance of a healthy and balanced diet for cancer patients
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas suggests that cancer…
11 Dec 2015
Addressing patient safety at the UKONS Annual Conference 2015
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom and beyond…
11 Dec 2015
Molecular drivers of metastatic disease in breast cancer
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that genetic…
11 Dec 2015
Clinical implications of malnourishment in cancer care
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…
11 Dec 2015
Nivolumab and cabozantinib versus standard of care in renal cell carcinoma
Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported…
11 Dec 2015
Overcoming acquired resistance to targeted therapies in lung cancer
At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that…
11 Dec 2015
The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells
At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study…
11 Dec 2015
The impact of the Oncotype DX® Breast Cancer Assay on the patient treatment journey
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…
11 Dec 2015
ASPIRE-PCa: Prospective, global observational study of men with late-stage prostate cancer
At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa…
11 Dec 2015
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a…
11 Dec 2015
Biomarker-driven therapies for triple-negative breast cancer
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups…
11 Dec 2015
Improving access to innovation in cancer care in Europe
At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology…
9 Dec 2015
Changing the standard of care in previously treated metastatic renal cell carcinoma
At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials…
9 Dec 2015
POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer
At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy…
9 Dec 2015
Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma
At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia…
9 Dec 2015
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris…
9 Dec 2015
Deciding which of the available genomic tests to use
Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in…
9 Dec 2015
Progress in the treatment of BRAF-mutant melanoma
At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the…
9 Dec 2015
BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer
At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single…
9 Dec 2015
BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer…
9 Dec 2015
MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma
At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety…
9 Dec 2015
Involving patients in the use of their data
Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis…
9 Dec 2015
2015 NCRI Cancer Conference highlights and new NCRI initiatives
Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference…
9 Dec 2015
Epigenetic targets in cancer
Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer…
9 Dec 2015
Breast Cancer Now: aiming to prevent death from breast cancer by 2050
Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that resulted from the combination of…
9 Dec 2015
Investigating the genomic landscape of brain tumours using metabolic imaging
Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he described a new…
9 Dec 2015
Systematic assessment of patient and carer needs in the oncology clinical and GP surgery
Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, that focuses on the…
9 Dec 2015
How many cancers can we prevent through dietary modifications?
Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. In his talk he discusses…
9 Dec 2015
Molecular testing for early cancer diagnosis: ready for prime time
Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, focusing…
9 Dec 2015
The origins of CDK by Tim Hunt
Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse and Leland Hartwell…
9 Dec 2015
Chemoprevention in breast cancer
Jack Cuzick, PhD, FMedSci, FRCP(hon), of the Queen Mary University of London, UK gives an overview of the session ‘Prevention is better than cure’…
9 Dec 2015
Tumour: stroma interactions
In the session ” Tumour: stroma interactions” presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, the importance of…
19 Nov 2015
Genomics England: 100,000 Genomes Project
Clare Turnbull, MD, PhD, gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where the Genomics…
19 Nov 2015
Reducing prostate cancer progression and mortality: what patients can do to reduce risk
Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how…
19 Nov 2015
Helping healthcare professionals initiate conversations about physical activity
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is implementing…
19 Nov 2015
Keeping active with Macmillan Cancer Support
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer Support initiative aimed…
19 Nov 2015
Physical activity – the panacea?
Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity – the panacea?” at the 2015 National Cancer Research Institute…
19 Nov 2015
The development of genomic tests and how validation affects their use in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…
19 Nov 2015
2015 NCRI Cancer Conference: Francis Crick Institute scientists
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered…
19 Nov 2015
Clonal evolution in colorectal cancer
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Alberto Bardelli, PhD talks about clonal evolution in colorectal cancer. He also…
19 Nov 2015
Update on CheckMate 067, an advanced melanoma clinical trial
James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab…
19 Nov 2015
Physical activity levels and barriers to exercise referral among patients with cancer
Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the…
19 Nov 2015
2015 NCRI Cancer Conference: Featured sessions
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…
19 Nov 2015
2015 NCRI Cancer Conference: The highlights
Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…
19 Nov 2015
Current status and future prospective of Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…
23 Oct 2015
Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…
23 Oct 2015
Immunotherapy: Targeting tumour heterogeneity
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
15 Oct 2015
New approaches to molecular cancer therapeutics
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
15 Oct 2015
The Patient Reported Opinions about Clinical Tolerability (PROACT)
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient…
15 Oct 2015
EURECCA international comparison of treatment patterns for non-metastatic breast cancer
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…
15 Oct 2015
Results from the ETOP Lungscape Project: Multiplex mutation testing in NSCLC
At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the…
15 Oct 2015
The causes and consequences of tumour evolution and heterogeneity
At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…
15 Oct 2015
Patient-centered partnership improve access to optimal standards of cancer care in Europe
European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40…
15 Oct 2015
ECC 2015: Press programme with updates on ‘Europe of Disparities in Cancer’
At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queen’s University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College…
15 Oct 2015
The discovery of new biomarkers for predicting outcomes in breast cancer
In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to…
15 Oct 2015
First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in…
15 Oct 2015
Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC
At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis…
15 Oct 2015
ECC 2015: News briefing chaired by Prof Peter Naredi
At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a news briefing with…
15 Oct 2015
Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer
At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim…
15 Oct 2015
ECC 2015: Cancer healthcare inequalities between and within countries in Europe
There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest…
15 Oct 2015
TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer
At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk…
15 Oct 2015
ECC 2015: Challenging the European disparities in cancer care
European Cancer Patient Coalition (ECPC), the largest European cancer patients’ umbrella organisation, presented the paper, ‘Europe of Disparities in…
15 Oct 2015
ECC 2015: Hormonal therapy may prevent ovarian failure and preserve fertility in breast cancer
A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without…
15 Oct 2015
Clinical access to genomic information in Europe
Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD…
14 Oct 2015
Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)
At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry…
14 Oct 2015
Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b…
14 Oct 2015
ECC 2015: Post-diagnosis aspirin improves survival in gastrointestinal cancers
Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall…
14 Oct 2015
ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma
Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…
14 Oct 2015
ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment
NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…
14 Oct 2015
ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours
RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US…
14 Oct 2015
ECC 2015: Launch of the European Society for Paediatric Oncology (SIOPE) strategic plan
The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field…
14 Oct 2015
ECC 2015: News briefing chaired by Prof Martine Piccart
At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…
14 Oct 2015
ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…
14 Oct 2015
ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…
14 Oct 2015
ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer
METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.
14 Oct 2015
The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…
14 Oct 2015
TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…
14 Oct 2015
Assessing the eligibility of a breast cancer patient for genomic testing
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…
14 Oct 2015
Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
14 Oct 2015
Experience of the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
15 Sep 2015
Genomic testing for breast cancer in the neoadjuvant setting
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…
15 Sep 2015
Introducing the Oncotype DX® Breast Cancer Assay and its impact in clinical practice
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…
15 Sep 2015
The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some…
15 Sep 2015
Introducing the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
15 Sep 2015
Refining the therapeutic approach for breast cancer through genomic profiling
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…
15 Sep 2015
Considerations when selecting a genomic test to use in specific breast cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…
9 Sep 2015
Genomic profiling for defining luminal subtypes
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
9 Sep 2015
Using genomic testing to access the suitability of breast cancer patients for chemotherapy
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the…
26 Aug 2015
Registry evaluating the impact of genomic testing on treatment of prostate cancer patients
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
26 Aug 2015
CancerLinQ: ASCO’s initiative to improve patient care through big data
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…
26 Aug 2015
ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
26 Aug 2015
Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen…
26 Aug 2015
An update on the treatment of chronic lymphocytic leukaemia
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing…
26 Aug 2015
HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY…
26 Aug 2015
IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides…
26 Aug 2015
CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…
26 Aug 2015
The evolving role of chemotherapy for the management of advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…
26 Aug 2015
Daratumumab for heavily pretreated multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta…
26 Aug 2015
Current clinical perspectives on targeted therapy and immunotherapy for melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France…
26 Aug 2015
ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the…
26 Aug 2015
Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…
26 Aug 2015
Frontline and relapsed treatment of follicular lymphoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…
26 Aug 2015
The Conquer Cancer Foundation of the American Society of Clinical Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center…
26 Aug 2015
Evaluating sustained adherence to ibrutinib in previously treated CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success…
21 Aug 2015
Therapy for newly diagnosed patients with mantle cell lymphoma
At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new…
21 Aug 2015
Introducing biomarkers for the management of patients with prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center…
21 Aug 2015
CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with breast cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides…
21 Aug 2015
Developing targeted therapies for melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney…
13 Aug 2015
Predicting late recurrence of breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Eleftherios P. Mamounas, MD, of University of Florida Health Cancer Center-Orlando…
13 Aug 2015
The management of breast cancer in the Japanese population
At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that there are still only…
13 Aug 2015
Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…
23 Jul 2015
PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2…
23 Jul 2015
Emerging immunotherapies for kidney cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
23 Jul 2015
Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK…
23 Jul 2015
ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…
23 Jul 2015
Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that…
23 Jul 2015
PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC…
23 Jul 2015
Immune responses and clinical outcomes in STAND trial of sipuleucel-T and ADT in prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…
23 Jul 2015
ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
23 Jul 2015
Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…
Loading posts...
« Previous
1
…
35
36
37
38
39
…
47
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View